Literature DB >> 24316945

Extended sacropelvic resection for locally recurrent rectal cancer: can it be done safely and with good oncologic outcomes?

Dorin T Colibaseanu1, Eric J Dozois, Kellie L Mathis, Peter S Rose, Maria L Martinez Ugarte, Zaid M Abdelsattar, Michael D Williams, David W Larson.   

Abstract

BACKGROUND: A multimodality approach to patients with locally recurrent rectal cancer that includes surgery is associated with a significant survival advantage when tumor-free margins are achieved. Patients with advanced tumors will require extended sacropelvic resection to optimize oncologic outcomes.
OBJECTIVE: The aim of this study was to assess the safety, feasibility, and oncologic outcomes of extended sacropelvic resection for locally recurrent rectal cancer at our institution.
DESIGN: A retrospective review identified 406 patients who had surgery for locally recurrent rectal cancer between 1997 and 2007. From this group, all patients who underwent a curative-intent sacropelvic resection were analyzed. SETTINGS: This investigation was conducted at an academic tertiary referral center. PATIENTS: Thirty patients (24 male) were identified. Median age was 59 years (range, 25-84). Operations were performed for a first local recurrence (n = 24), a second recurrence (n = 5) and for a third recurrence (n = 1).
INTERVENTIONS: Twenty-six patients underwent neoadjuvant radiation, and 20 received intraoperative radiation therapy. All patients underwent extended sacropelvic resection. MAIN OUTCOME MEASURES: The primary outcomes measured were early (<30 days) and late (>30 days) surgical complications. Overall and disease-free survivals were estimated by using the Kaplan-Meier technique.
RESULTS: Margin-negative resection was achieved in 93%. The most proximal level of spinal transection was the fourth lumbar space, and 4 patients underwent lower extremity amputation. There was no mortality, and early morbidity was seen in 76%. Median follow-up was 2.7 years (range, 2 months to 10.8 years). Overall survival at 2 and 5 years was 86% and 46%. Disease-free survival at 2 and 5 years was 79% and 43%. LIMITATIONS: This study was limited by its retrospective nature and the limited number of patients.
CONCLUSIONS: We found extended sacropelvic resection for locally recurrent rectal cancer to be feasible and safe with overall and disease-free survival rates in comparison with survival rates seen in patients undergoing nonsacropelvic resections for locally recurrent rectal cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24316945     DOI: 10.1097/DCR.0000000000000015

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  9 in total

1.  Factors associated with the location of local rectal cancer recurrence and predictors of survival.

Authors:  Peng Du; John P Burke; Wisam Khoury; Ian C Lavery; Ravi P Kiran; Feza H Remzi; David W Dietz
Journal:  Int J Colorectal Dis       Date:  2016-02-10       Impact factor: 2.571

Review 2.  Surgery for Locally Recurrent Rectal Cancer: Tips, Tricks, and Pitfalls.

Authors:  Satish K Warrier; Alexander G Heriot; Andrew Craig Lynch
Journal:  Clin Colon Rectal Surg       Date:  2016-06

3.  Posterior high sacral segmental disconnection prior to anterior en bloc exenteration for recurrent rectal cancer.

Authors:  K G M Brown; M J Solomon; K K S Austin; P J Lee; P Stalley
Journal:  Tech Coloproctol       Date:  2016-03-21       Impact factor: 3.781

Review 4.  National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States.

Authors:  Arnold Pompos; Robert L Foote; Albert C Koong; Quynh Thu Le; Radhe Mohan; Harald Paganetti; Hak Choy
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

5.  State-of-the-art surgery for recurrent and locally advanced rectal cancers.

Authors:  Mufaddal Kazi; Vivek Sukumar; Ashwin Desouza; Avanish Saklani
Journal:  Langenbecks Arch Surg       Date:  2021-08-02       Impact factor: 3.445

6.  Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series.

Authors:  L G P H Vroomen; H J Scheffer; M C A M Melenhorst; N van Grieken; M P van den Tol; M R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-03       Impact factor: 2.740

7.  CT-guided cryoablation for unresectable pelvic recurrent colorectal cancer: a retrospective study.

Authors:  Ying Wang; Xin-Hong He; Li-Chao Xu; Hao-Zhe Huang; Guo-Dong Li; Yao-Hui Wang; Wen-Tao Li; Guang-Zhi Wang
Journal:  Onco Targets Ther       Date:  2019-02-19       Impact factor: 4.147

8.  An In Vivo Mouse Model of Pelvic Recurrence of Human Colorectal Cancer.

Authors:  Masashi Yamamoto; Kohei Taniguchi; Shinsuke Masubuchi; Tomo Tominaga; Yosuke Inomata; Akiko Miyamoto; Taka-Aki Ishizuka; Takashi Murakami; Wataru Osumi; Hiroki Hamamoto; Keitaro Tanaka; Junji Okuda; Kazuhisa Uchiyama
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379

Review 9.  Surgical treatment of locally recurrent rectal cancer: a narrative review.

Authors:  Zhaoya Gao; Jin Gu
Journal:  Ann Transl Med       Date:  2021-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.